In IBD patients after the remission of intestinal inflammation by Infliximab, a chimeric monoclonal anti-TNF-α antibody, the upregulated MMPs and TIMPs, including MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2, were recessed [59]. Here, MMP3 is linked to irritable bowel syndrome.